leadf
logo-loader
AIM:EVG FRA:8EV

Evgen Pharma PLC

Receive alerts
Market:
AIM
Market Cap:
£14.5 m
Price
10.55 GBX
Change
-1.86%
52 weeks high
17.00
52 weeks low
2.50

In brief

Evgen Pharma is a clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases. Our pipeline is derived from our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications.

Insight Widest with the analysis, Proactive gives perspectives that others don't.

AstraZeneca and the art of resurrecting failed drug candidates

Mereo and Evgen's drugs both stumbled as phase 2 trials yielded disappointing results, but an AstraZeneca-style turnaround could be around the corner

on 12/11/19